Microtubule-binding agents: a dynamic field of cancer therapeutics

C Dumontet, MA Jordan - Nature reviews Drug discovery, 2010 - nature.com
Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an
important therapeutic target in tumour cells. Agents that bind to microtubules have been part …

Taxanes in cancer treatment: Activity, chemoresistance and its overcoming

L Mosca, A Ilari, F Fazi, YG Assaraf, G Colotti - Drug Resistance Updates, 2021 - Elsevier
Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Microtubule targeting agents in disease: classic drugs, novel roles

L Wordeman, JJ Vicente - Cancers, 2021 - mdpi.com
Simple Summary Microtubules (MTs) are highly conserved proteins present in all eukaryotic
organisms. They form the cell cytoskeleton, and its function is essential for a large number of …

Taxol®: The First Microtubule Stabilizing Agent

CPH Yang, SB Horwitz - International journal of molecular sciences, 2017 - mdpi.com
Taxol®, an antitumor drug with significant activity, is the first microtubule stabilizing agent
described in the literature. This short review of the mechanism of action of Taxol® …

Taxanes, microtubules and chemoresistant breast cancer

BT McGrogan, B Gilmartin, DN Carney… - Biochimica et Biophysica …, 2008 - Elsevier
The taxanes, paclitaxel and docetaxel are microtubule-stabilizing agents that function
primarily by interfering with spindle microtubule dynamics causing cell cycle arrest and …

Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains

F Naaz, MR Haider, S Shafi, MS Yar - European journal of medicinal …, 2019 - Elsevier
Microtubules are a protein which is made of α-and β-heterodimer. It is one of the main
components of the cell which play a vital role in cell division especially in G2/M-phase. It …

Role of microRNAs in drug-resistant ovarian cancer cells

A Sorrentino, CG Liu, A Addario, C Peschle… - Gynecologic …, 2008 - Elsevier
OBJECTIVES: Chemotherapy is the preferred therapeutic approach for the therapy of
advanced ovarian cancer, but a successful long-term treatment is prevented by the …

Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy

KE Arnst, S Banerjee, H Chen, S Deng… - Medicinal research …, 2019 - Wiley Online Library
Microtubule (MT)‐targeting agents are highly successful drugs as chemotherapeutic agents,
and this is attributed to their ability to target MT dynamics and interfere with critical cellular …

[PDF][PDF] A review on “Imidazoles”: Their chemistry and pharmacological potentials

A Bhatnagar, PK Sharma, N Kumar - Int J PharmTech Res, 2011 - academia.edu
Introduction: Imidazole is an entity which is being synthesized in many of its derivative form
from past few years; the entity is major source of interest for many of medicinal chemist to …

Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?

P Sève, C Dumontet - The lancet oncology, 2008 - thelancet.com
On the basis of preclinical studies that show overexpression of class III β-tubulin is
associated with resistance to tubulin-binding agents, several investigators have addressed …